{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:42:58Z","timestamp":1789191778194,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100016003","name":"Istanbul University Cerrahpa\u015fa","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100016003","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>In advanced-stage classical Hodgkin lymphoma (cHL), the prognosis has improved due to combination chemotherapy and PET\/CT-guided treatment modification, resulting in a decreased prognostic capacity of IPS models. A novel model, A-HIPI, was found to be superior to IPS in predicting prognosis. In this study, we aimed to validate the A-HIPI model among Turkish cHL patients and compare its performance with other clinical prediction models. We retrospectively evaluated patients diagnosed with advanced-stage cHL between 2005 and 2018 at Istanbul University-Cerrahpa\u015fa. We used IPS-7, IPS-3, and A-HIPI scores to calculate the C-index (Harrell\u2019s Concordance Index) for discrimination; calibration intercept, and calibration slope for calibration. The models were compared using Akaike\u2019s Information Criterion (AIC). Two hundred and seven patients were enrolled with a median follow-up of 75 months, 37 patients (17.9%) died. The 5-year PFS and OS were 66.6% and 84.9%, respectively. All three models were found to be prognostic for PFS and OS. The A-HIPI model was well-calibrated for PFS and OS in patients aged \u226465 years, but not calibrated for patients aged\u2009&gt;\u200965 years. With A-HIPI, the respective C-index for PFS and OS was 0.605 and 0.740; whereas, for IPS-7 it was 0.598 and 0.684, and for IPS-3 it was 0.624 and 0.705. The lowest AIC value for OS was observed with the A-HIPI. The lowest AIC value for PFS was observed with IPS-3. This study validated the A-HIPI model in a homogeneous patient group for treatment protocol, with all follow-ups performed at a single center after the early 2000s in Turkey. The A-HIPI model demonstrated better performance than other models, except for patients aged\u2009&gt;\u200965 years. A new clinical prediction model is needed for patients\u2009&gt;\u200965 years, as IPS models are out of date and A-HIPI has not been validated for this group.<\/jats:p>","DOI":"10.1007\/s00277-025-06292-3","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T01:34:06Z","timestamp":1741743246000},"page":"1765-1775","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The validation of advanced-stage Hodgkin lymphoma international prognostic index (A-HIPI) in Turkish patients with classical Hodgkin lymphoma"],"prefix":"10.1007","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1239-3246","authenticated-orcid":false,"given":"Oguzhan","family":"Koca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berk","family":"Ozyurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysenur","family":"Umar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"Ozmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tugrul","family":"Elverdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayse","family":"Salihoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhlis Cem","family":"Ar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zafer","family":"Baslar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9568-0894","authenticated-orcid":false,"given":"Ahmet Emre","family":"Eskazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"6292_CR1","doi-asserted-by":"publisher","unstructured":"Hodgkin (1832) On some morbid appearances of the absorbent glands and spleen. J R Soc Med MCT\u201317:68\u2013114. https:\/\/doi.org\/10.1177\/095952873201700106","DOI":"10.1177\/095952873201700106"},{"key":"6292_CR2","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of hodgkin and Non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059\u20133067. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"key":"6292_CR3","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1000067","volume":"363","author":"A Engert","year":"2010","unstructured":"Engert A, Pl\u00fctschow A, Eich HT et al (2010) Reduced treatment intensity in patients with Early-Stage Hodgkin\u2019s lymphoma. N Engl J Med 363:640\u2013652. https:\/\/doi.org\/10.1056\/NEJMoa1000067","journal-title":"N Engl J Med"},{"key":"6292_CR4","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1093\/annonc\/mdt413","volume":"24","author":"B Klimm","year":"2013","unstructured":"Klimm B, Goergen H, Fuchs M et al (2013) Impact of risk factors on outcomes in early-stage Hodgkin\u2019s lymphoma: an analysis of international staging definitions. Ann Oncol 24:3070\u20133076. https:\/\/doi.org\/10.1093\/annonc\/mdt413","journal-title":"Ann Oncol"},{"key":"6292_CR5","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","volume":"339","author":"D Hasenclever","year":"1998","unstructured":"Hasenclever D, Diehl V, Armitage JO et al (1998) A prognostic score for advanced Hodgkin\u2019s disease. N Engl J Med 339:1506\u20131514. https:\/\/doi.org\/10.1056\/NEJM199811193392104","journal-title":"N Engl J Med"},{"key":"6292_CR6","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.2011.41.0910","volume":"30","author":"AA Moccia","year":"2012","unstructured":"Moccia AA, Donaldson J, Chhanabhai M et al (2012) International prognostic score in Advanced-Stage Hodgkin\u2019s lymphoma: altered utility in the modern era. J Clin Oncol 30:3383\u20133388. https:\/\/doi.org\/10.1200\/JCO.2011.41.0910","journal-title":"J Clin Oncol"},{"key":"6292_CR7","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/bjh.13634","volume":"171","author":"CS Diefenbach","year":"2015","unstructured":"Diefenbach CS, Li H, Hong F et al (2015) Evaluation of the international prognostic score (IPS-7) and a simpler prognostic score (IPS-3) for advanced hodgkin lymphoma in the modern era. Br J Haematol 171:530\u2013538. https:\/\/doi.org\/10.1111\/bjh.13634","journal-title":"Br J Haematol"},{"key":"6292_CR8","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.3109\/10428194.2013.798868","volume":"54","author":"S Arai","year":"2013","unstructured":"Arai S, Fanale M, deVos S et al (2013) Defining a hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma 54:2531\u20132533. https:\/\/doi.org\/10.3109\/10428194.2013.798868","journal-title":"Leuk Lymphoma"},{"key":"6292_CR9","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.2147\/CMAR.S363235","volume":"14","author":"S \u00c7okgezer","year":"2022","unstructured":"\u00c7okgezer S, Elverdi T, Saliho\u011flu A et al (2022) Treatment responses, toxicity, and survival in patients with classical hodgkin lymphoma aged \u2265 50 years: A Single-Center experience over two decades. Cancer Manag Res 14:1911\u20131921. https:\/\/doi.org\/10.2147\/CMAR.S363235","journal-title":"Cancer Manag Res"},{"key":"6292_CR10","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa0905680","volume":"362","author":"C Steidl","year":"2010","unstructured":"Steidl C, Lee T, Shah SP et al (2010) Tumor-Associated macrophages and survival in classic Hodgkin\u2019s lymphoma. N Engl J Med 362:875\u2013885. https:\/\/doi.org\/10.1056\/NEJMoa0905680","journal-title":"N Engl J Med"},{"key":"6292_CR11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3324\/haematol.2010.031542","volume":"96","author":"P Kamper","year":"2011","unstructured":"Kamper P, Bendix K, Hamilton-Dutoit S et al (2011) Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin\u2019s lymphoma. Haematologica 96:269\u2013276. https:\/\/doi.org\/10.3324\/haematol.2010.031542","journal-title":"Haematologica"},{"key":"6292_CR12","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1182\/blood-2012-04-421057","volume":"120","author":"KL Tan","year":"2012","unstructured":"Tan KL, Scott DW, Hong F et al (2012) Tumor-associated macrophages predict inferior outcomes in classic hodgkin lymphoma: a correlative study from the E2496 intergroup trial. Blood 120:3280\u20133287. https:\/\/doi.org\/10.1182\/blood-2012-04-421057","journal-title":"Blood"},{"key":"6292_CR13","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3109\/10428194.2014.917636","volume":"56","author":"M Touati","year":"2015","unstructured":"Touati M, Delage-Corre M, Monteil J et al (2015) CD68-positive tumor-associated macrophages predict unfavorable treatment outcomes in classical hodgkin lymphoma in correlation with interim fluorodeoxyglucose-positron emission tomography assessment. Leuk Lymphoma 56:332\u2013341. https:\/\/doi.org\/10.3109\/10428194.2014.917636","journal-title":"Leuk Lymphoma"},{"key":"6292_CR14","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1200\/JCO.2012.43.4589","volume":"31","author":"DW Scott","year":"2013","unstructured":"Scott DW, Chan FC, Hong F et al (2013) Gene Expression\u2013Based model using Formalin-Fixed Paraffin-Embedded biopsies predicts overall survival in Advanced-Stage classical hodgkin lymphoma. J Clin Oncol 31:692\u2013700. https:\/\/doi.org\/10.1200\/JCO.2012.43.4589","journal-title":"J Clin Oncol"},{"key":"6292_CR15","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1182\/blood-2012-09-454694","volume":"121","author":"JA Kanakry","year":"2013","unstructured":"Kanakry JA, Li H, Gellert LL et al (2013) Plasma Epstein-Barr virus DNA predicts outcome in advanced hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood 121:3547\u20133553. https:\/\/doi.org\/10.1182\/blood-2012-09-454694","journal-title":"Blood"},{"key":"6292_CR16","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1200\/JCO.22.02473","volume":"41","author":"AM Rodday","year":"2023","unstructured":"Rodday AM, Parsons SK, Upshaw JN et al (2023) The Advanced-Stage hodgkin lymphoma international prognostic index: development and validation of a clinical prediction model from the holistic consortium. J Clin Oncol 41:2076\u20132086. https:\/\/doi.org\/10.1200\/JCO.22.02473","journal-title":"J Clin Oncol"},{"key":"6292_CR17","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1001\/jama.2017.12126","volume":"318","author":"AC Alba","year":"2017","unstructured":"Alba AC, Agoritsas T, Walsh M et al (2017) Discrimination and calibration of clinical prediction models. JAMA 318:1377. https:\/\/doi.org\/10.1001\/jama.2017.12126","journal-title":"JAMA"},{"key":"6292_CR18","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12916-019-1466-7","volume":"17","author":"B Van Calster","year":"2019","unstructured":"Van Calster B, McLernon DJ, van Smeden M et al (2019) Calibration: the Achilles heel of predictive analytics. BMC Med 17:230. https:\/\/doi.org\/10.1186\/s12916-019-1466-7","journal-title":"BMC Med"},{"key":"6292_CR19","unstructured":"Burnham KP, Anderson DR (2002) Model selection and multimodel inference: A practical Information-Theoretic approach. Springer Nature"},{"key":"6292_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1136\/adc.74.1.27","volume":"74","author":"M Weinreb","year":"1996","unstructured":"Weinreb M, Day PJ, Niggli F et al (1996) The role of Epstein-Barr virus in Hodgkin\u2019s disease from different geographical areas. Arch Dis Child 74:27\u201331. https:\/\/doi.org\/10.1136\/adc.74.1.27","journal-title":"Arch Dis Child"},{"key":"6292_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.4274\/tjh.galenos.2024.2024.0181","volume":"41","author":"D Brittain","year":"2024","unstructured":"Brittain D, Akhtar S, Rodrigues S et al (2024) Treatment patterns and clinical outcomes in patients with hodgkin lymphoma from Saudi Arabia, T\u00fcrkiye, and South Africa: subgroup analysis from the international multicenter retrospective B-HOLISTIC study. Turk J Haematol 41:211\u2013224. https:\/\/doi.org\/10.4274\/tjh.galenos.2024.2024.0181","journal-title":"Turk J Haematol"},{"key":"6292_CR22","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/ijc.31096","volume":"142","author":"I Biasoli","year":"2018","unstructured":"Biasoli I, Castro N, Delamain M et al (2018) Lower socioeconomic status is independently associated with shorter survival in hodgkin lymphoma patients\u2014An analysis from the Brazilian hodgkin lymphoma registry. Int J Cancer 142:883\u2013890. https:\/\/doi.org\/10.1002\/ijc.31096","journal-title":"Int J Cancer"},{"key":"6292_CR23","doi-asserted-by":"publisher","first-page":"6200","DOI":"10.1182\/BLOOD-2023-173318","volume":"142","author":"I Biasoli","year":"2023","unstructured":"Biasoli I, Buccheri V, Moreira FR et al (2023) External validation of the Advanced-Stage hodgkin lymphoma international prognostic index (A-HIPI): strong calibration in the Brazilian prospective hodgkin lymphoma registry. Blood 142:6200. https:\/\/doi.org\/10.1182\/BLOOD-2023-173318","journal-title":"Blood"},{"key":"6292_CR24","doi-asserted-by":"publisher","first-page":"4455","DOI":"10.1182\/blood-2023-178498","volume":"142","author":"RK J\u00f8rgensen","year":"2023","unstructured":"J\u00f8rgensen RK, Eloranta R, Christensen S JH, et al (2023) Age-Based validation of the Advanced-Stage hodgkin lymphoma international prognostic index (A-HIPI) in a Real-World Danish study: suboptimal performance in older patients. Blood 142:4455. https:\/\/doi.org\/10.1182\/blood-2023-178498","journal-title":"Blood"},{"key":"6292_CR25","doi-asserted-by":"crossref","unstructured":"Cellini A, Adele Cavarretta C, Angotzi F et al (2023) P1075: ADVANCED-STAGE CHL INTERNATIONAL PROGNOSTICATION INDEX: EXTERNAL VALIDATION IN A SINGLE-CENTER RETROSPECTIVE PATIENT DATASET AND COMPARISON TO THE HASENCLEVER IPS. Hemasphere 7","DOI":"10.1097\/01.HS9.0000971196.13252.3d"},{"key":"6292_CR26","doi-asserted-by":"publisher","unstructured":"Br\u00f6ckelmann PJ, M\u00fcller H, Fuchs M et al (2024) Correlation between progression-free and overall survival in patients with hodgkin lymphoma: a comprehensive analysis of individual patient data from randomized German hodgkin study group (GHSG) trials. https:\/\/doi.org\/10.1016\/j.annonc.2024.12.009. Annals of Oncology","DOI":"10.1016\/j.annonc.2024.12.009"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06292-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06292-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06292-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T10:10:27Z","timestamp":1745575827000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06292-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["6292"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06292-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"6 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by Istanbul University-Cerrahpasa clinical research ethics committee. The study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}